Sensorion (ALSEN.PA) Saham Harga
Sensorion Harga
Selama 13 tahun terakhir pendapatan Sensorion tumbuh 164,9% per tahun, mencapai 6,65 Juta. EUR. Bagi Sensorion, margin bersih sebesar -390,4% turun dibanding -381,7% beberapa tahun lalu. Target harga konsensus 12 bulan untuk Sensorion adalah 2,04 EUR, sekitar di bawah harga saat ini 67,5%. Dari 13 analis, 12 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Sensorion
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Sensorion
Pertanyaan yang sering diajukan tentang saham Sensorion
Sensorion SA is a biopharmaceutical company specializing in the development of innovative therapies to address inner ear disorders. The company's business model revolves around the research, development, and commercialization of novel treatments for conditions such as vertigo and hearing loss. Sensorion SA aims to leverage its expertise in inner ear biology and drug development to create innovative therapies that can provide significant benefits to patients. With a focus on advancing its proprietary pipeline of drug candidates, Sensorion SA is dedicated to meeting the unmet medical needs in the field of inner ear disorders.
Sensorion SA is primarily active in the biotechnology industry.
The main competitors of Sensorion SA in the market are [competitor #1], [competitor #2], and [competitor #3]. These companies operate in the same industry as Sensorion SA and provide similar products or services. Despite facing competition, Sensorion SA has positioned itself as a key player in the market with its unique offerings. By continually innovating and delivering high-quality solutions, Sensorion SA maintains a competitive edge in the industry.
Sensorion SA is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for inner ear disorders. Founded in 2009, Sensorion has a strong focus on addressing unmet medical needs in the field of hearing loss and vestibular disorders. The company's research and development efforts primarily revolve around the identification, selection, and development of small molecules designed to protect, regenerate, and restore inner ear cells. With a deep commitment to improving the quality of life for patients suffering from hearing and balance disorders, Sensorion SA continues to pursue groundbreaking solutions to these debilitating conditions.
Sensorion SA, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, the company successfully completed Phase 1 clinical trials for its novel therapy targeting inner ear disorders. It also received Orphan Drug Designation from the FDA for its product candidate, confirming its potential to address unmet medical needs. Furthermore, Sensorion SA successfully initiated Phase 2 clinical trials, demonstrating promising results in patients with sudden sensorineural hearing loss. The company's collaborations with renowned academic institutions highlight its commitment to advancing research in the field. Overall, Sensorion SA's achievements reflect its dedication to revolutionizing treatments for inner ear disorders, positioning it as a key player in the industry.
Sensorion SA is primarily present in several countries and regions globally. These include the United States, Europe, and Asia. The company has established a strong presence in the United States, where it conducts significant research and development activities. In Europe, Sensorion SA has partnerships and collaborations with various academic institutions and pharmaceutical companies. Additionally, the company has expanded its reach in Asia through strategic alliances and distribution agreements. With its global presence, Sensorion SA aims to address the unmet medical needs of patients suffering from inner ear disorders and provide innovative solutions in the field of hearing and balance disorders.
Sensorion SA is a leading biopharmaceutical company dedicated to developing innovative therapies for inner ear disorders. The company's values revolve around scientific excellence, patient-centered approach, and commitment to improving the lives of individuals suffering from vestibular and hearing impairments. Sensorion SA aims to provide effective and safe treatment solutions while prioritizing the needs and well-being of patients. With a strong corporate philosophy grounded in research and development, Sensorion SA strives to address the unmet medical needs in the field of auditory disorders, aiming to make a meaningful impact on the lives of individuals affected by these conditions.
Analis saat ini menetapkan target harga rata-rata 1,94 EUR untuk saham Sensorion (median: 2,04 EUR), yaitu -69,1 % terhadap harga terbaru. Konsensus didasarkan pada 13 peringkat analis.
14 analis saat ini menilai saham Sensorion: 13 merekomendasikan beli, 1 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Sensorion menghasilkan pendapatan 4,55 Juta. EUR dan laba per saham -169,83 EUR.
Saham Sensorion (ALSEN.PA) tercatat di 5 bursa, termasuk: Frankfurt (RFM.F), München (RFM.MU), Düsseldorf (RFM.DU), Paris (ALSEN.PA).
Sensorion SA is a French biotechnology company specializing in the development of novel therapies for the treatment of inner ear disorders and hearing loss. The company focuses on researching and developing drugs tailored to the specific needs of patients. Sensorion aims to create innovative products and therapies in the field of otolaryngology to meet the needs of patients.
Pendapatan diperkirakan dari Sensorion adalah 4,55 Juta. EUR. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Sensorion adalah -1,02 miliar EUR. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Sensorion saat ini adalah -0,04. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Sensorion.
Rasio harga-terhadap-penjualan (PSR) Sensorion saat ini adalah 8,29. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Sensorion.
Skor Kualitas AlleAktien untuk Sensorion adalah 2/10.
ISIN dari Sensorion adalah FR0012596468. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Sensorion adalah A14SVV. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Sensorion adalah ALSEN.PA. Simbol ticker digunakan untuk memperdagangkan saham Sensorion di bursa saham.
Saham Sensorion
Kelompok Peer Sensorion
Sensorion Ticker
Sensorion FIGI
Semua metrik fundamental dan analisis mendalam Sensorion
Analisis saham kami untuk saham Sensorion mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Sensorion. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.